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Abstract 
Aims: Previously, detection of ANO5 protein has been complicated by unspecific 
antibodies, most of which have not identified the correct protein. The aims of the 
study were to specify ANO5 protein expression in human skeletal muscle, and to 
investigate if the ANO5 protein levels are affected by different ANO5 mutations in 
anoctaminopathy patients. 
Methods: Four different antibodies were tested for ANO5 specificity. A sample 
preparation method compatible with membrane proteins, combined with tissue 
fractionation was used to determine ANO5 expression in cell cultures expressing 
ANO5, in normal muscles and eight patient biopsies with six different ANO5 
mutations in homozygous or compound heterozygous states, and in other dystrophies.  
Results: Only one specific monoclonal N-terminal ANO5 antibody was efficient in 
detecting the protein, showing that ANO5 is expressed as a single 107 kD polypeptide 
in human skeletal muscle. The truncating mutations c.191dupA and c.1261C>T were 
found to abolish ANO5 expression, whereas the studied point mutations had variable 
effects, however, all the ANO5 mutations resulted in clearly reduced ANO5 
expression in the patient muscle membrane fraction. Attempts to detect ANO5 using 
immunohistochemistry were not yet successful. 
Conclusions: The data presented here indicate that the ANO5 protein expression is 
decreased in ANO5-mutated muscular dystrophy and that most of the non-truncating 
pathogenic ANO5 mutations likely destabilize the protein and cause its degradation. 
The method described here allows direct analysis of human ANO5 protein, which can 
be used in diagnostics, for evaluating the pathogenicity of the potentially harmful 
ANO5 variants of uncertain significance. 
  
Introduction 
The limb-girdle muscular dystrophies (LGMDs) comprise a genetically complex 
group of muscular diseases affecting preferably proximal muscles [1]. The human 
ANO5 (TMEM16E) gene harbors >70 recessive mutations causing adult-onset muscle 
phenotypes such as limb-girdle muscular dystrophy type 2L (LGMD2L; OMIM 
611307) and Miyoshi muscular dystrophy -like disease with distal phenotype 
(MMD3; OMIM 613319) [2-5]. 
 
Clinical features can vary from just high CK levels, mild weakness and exercise 
myalgia to more severe muscular atrophies. Weakness can be proximal, distal, or both 
in some cases [3, 4, 6]. Asymmetric muscle involvement and gender imbalance, men 
being more frequently and more severely affected, are features of anoctaminopathy. 
No clear genotype-phenotype correlation has been found [3, 6]. Dominant mutations 
in ANO5 affecting the amino acid C356 cause a completely different phenotype: 
gnathodiaphyseal dysplasia (GDD; OMIM #166260), a skeletal syndrome [7, 8]. 
 
The anoctamin/TMEM16 family of genes, ANO1 – ANO10, encodes for 10 eight-pass 
transmembrane proteins with diverse physiological functions, including Ca2+ activated 
Cl- channels, cation channels and lipid scramblases [9]. However, ANO5 does not 
show any of these activities [10, 11]. A recent report on ANO5 deficient mouse model 
suggested that ANO5 has a role in muscle membrane repair and regeneration [12]. 
The human ANO5 gene is transcribed into one protein-coding mRNA species with 22 
exons, giving rise to a 913 amino acid, 107 kD ANO5 protein (TMEM16E) (Uniprot 
Q75V66-1). The functions of ANO5 are not fully clarified, although it may have a 
role in membrane dynamics [12]. 
 A major restriction for ANO5 research involving human patients has been the lack of 
specific antibodies. Here we describe a western blotting method to study ANO5 
protein expression in human muscle biopsies and subcellular fractions. The method 
described here enables analyzing the consequences of different ANO5 mutations at 
protein level. 
 
  
Materials and Methods 
Patients  
Biopsies were taken for diagnostic purpose and informed consent was obtained from 
all individual participants included in the study, according to the Declaration of 
Helsinki, and approved by the institutional review boards. Altogether eight 
anoctaminopathy patients (four Finnish, one French and three Italian), homozygous or 
compound heterozygous for pathogenic ANO5 mutations, were included (Table 1 and 
Supplemental Figure S1). One patient with undefined myopathy, heterozygous for one 
ANO5 anomaly at mRNA level, was used as a carrier control. In addition, 11 control 
individuals free of muscular disease were included (Table 2).  
 
Constructs 
The plasmid expression vector containing the wild-type full-length human ANO5 
cDNA tagged with V5 epitope at its 3´end, hANO5wt-V5, has been described 
previously as hGDD1-V5 [8]. 
 
Cell culture and transfection 
COS-1 cells (ATCC, Manassas, VA, USA) were cultured at +38°C, 5% CO2, in 
DMEM supplemented with 10% FCS, 1% PenStrep and 1% Glutamax. For 
transfection experiments, COS-1 cells were seeded on 6-well plates and grown to 60-
70% confluence overnight. The next day, the cells were transfected with hANO5wt-
V5 using FuGene 6 (Promega, Madison, WI, USA), with DNA (µg):FuGene 6 (µl) 
ratio 1:3. Two days after transfection the cells were harvested for western blotting. 
Untransfected COS-1 cells were used as negative control. 
 
Subcellular protein fractionation 
Frozen muscle sections (40–60 x 12 µm) were placed in pre-chilled microcentrifuge 
tubes, and ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, Merck 
KGaA, Darmstadt, Germany) was used to separate soluble, insoluble and membrane 
protein fractions. The extraction was performed according to the manufacturer's 
instructions.  
 
ANO5 western blotting 
The membrane protein fractions were placed on ice and sonicated in water bath 
sonicator 3 x 1 min, cooling on ice in between pulses. Alternatively, RIPA buffer, pH 
8.0, supplemented with HALT/EDTA Protease Inhibitor Cocktail (100x) (Thermo 
Fisher Scientific, Waltham, MA, USA) was added to frozen muscle sections in pre-
cooled microcentrifuge tubes, lysed by vortexing for 10 sec, and sonicated as above. 
Laemmli sample buffer (1x) and beta-mercaptoethanol (10%) were added, and the 
samples were incubated for 10 min at room temperature. Solution was centrifuged for 
5 min, 16 000 g, and supernatant was used for SDS-PAGE and western blotting onto 
PVDF membranes using conventional methods. For COS-1 cells, 220 µl RIPA with 
protease inhibitors was added to a single well on 6-well plate, and the cells were 
collected in a microcentrifuge tube using a cell scraper. The samples were processed 
by vortexing and sonication, as described above. 
 
PVDF filters were detected using primary ANO5 mAb N421A/85 (UC Davis/NIH 
NeuroMab, Davis, CA, USA), raised against human ANO5 aa 1-299, at dilution 1:20 
in TBST/5% non-fat milk powder solution overnight at +8°, with gentle agitation. 
Super Signal Femto (Pierce, Thermo Fisher Scientific) substrate at dilution 2:5 (in 
PBS) was used for ECL reaction, and the signal was detected with ChemiDoc reader 
(Bio-Rad Laboratories, CA, USA). Appropriate loading controls were used for 
different samples: myosin heavy chain (MyHC) band, stained with Coomassie 
Brilliant Blue, for total muscle extracts and insoluble fractions; GAPDH (ab8245, 
Abcam, Cambridge, UK) for COS-1 cells and muscle soluble fractions; pooled 
SERCA1/SERCA2 (clone VE121G9, Research Diagnostics Inc., NJ, USA and 
ab2817, Abcam, respectively) or DHPR (ab2862, Abcam) for muscle membrane 
fractions. V5 antibody (clone SV5-P-k, Invitrogen) was used to detect the V5-tagged 
constructs. 
 
The ANO5, SERCA(1/2) and DHPR bands were quantitated using the ImageLab v5.0 
software (BioRad) to obtain band volumes (integrated densities). Next, the 
ANO5/SERCA and ANO5/DHPR ratios were calculated for each sample. Average 
values of all control samples were calculated and normalized to 1, in order to get the 
relative expression of ANO5 in each patient. 
 
 
  
Results  
In transfected COS-1 cells, western blotting revealed a band migrating just above the 
100 kD marker, with both V5 and ANO5 N421A/85 antibodies, corresponding with 
the size of the expressed hANO5wt-V5 construct (109 kD) (Figure 1A). An additional 
>200 kD band was observed, likely representing ANO5 dimers. Three other ANO5 
antibodies, one commercial and two custom-made, were tested as well, but they failed 
to recognize specifically the ANO5 protein in Western blotting (Supplemental Figure 
S2). 
 
Next, muscle biopsy sections from normal controls and ANO5 patients were prepared 
into WB samples. A band of ~100 kD was observed in control muscle extracts, 
whereas this band seemed reduced to some extent in all patients (Figure 1B). No 
truncated ANO5 polypeptides were observed with the N-terminal ANO5 N421A/85 
antibody. Several bands of different molecular weights were observed as well, but 
they were interpreted as unspecific, as they were present in all controls and patients 
tested. Notably, there were also unspecific bands just above and beneath of the full-
length ANO5, making reliable quantitation of specific bands impossible. 
 
In order to study the ANO5 subcellular distribution, and to eliminate unspecific 
bands, we performed muscle tissue fractionation and analyzed the soluble (F1), 
membranous (F2) and insoluble (F4) fractions in controls and three ANO5 patients. In 
all controls and in patient Fin3 (c.2272C/c.2272C), a single ~100 kD ANO5 band was 
clearly seen in the membrane fraction F2, but hardly detectable in patients Fin5 (c. 
2272C>T/c.191dupA) and Ita3 (c.191dupA/c.191dupA) (Figure 1C). Notably, most 
unspecific bands were found in the soluble fraction F1. 
 We then quantitated the ANO5 protein bands in membrane fractions of six controls 
and seven anoctaminopathy patients (Figure 2A), and determined the relative 
expression by calculating the ANO5/SERCA and ANO5/DHPR ratios (Figure 2B). 
The results were uniform with both membrane protein markers, showing that ANO5 
was clearly decreased in all patients. The c.191dupA homozygous patient Ita3 showed 
only residual ANO5 expression, as expected; otherwise no clear correlation in 
expression could be seen with different mutations.  
 
Because of the relatively selective involvement of different muscles in 
anoctaminopathy, we assessed the ANO5 protein expression level in a set of different 
control muscles. However, in the muscles tested (gastrocnemius, tibialis anterior, 
biceps femoris and semimembranosus), there were very small differences in the 
expression levels between individual specimens, but no marked differences between 
the different muscle groups (Supplemental Figure S3). A band of ~100 kD was 
consistently seen, and no sign of possible isoform variation.  
 
Immunohistochemistry experiments were not successful in obtaining specific labeling 
using human muscle biopsies, probably due to too low affinity for the natural 
conformation of the protein (Supplemental Figure S4). 
All the experiments were replicated 2-4 times, giving highly reproducible results.  
Discussion 
Setting up a reliable method to detect endogenous ANO5 protein has proved to be 
very challenging. Previous attempts to determine ANO5 expression have been 
complicated by the high degree of unspecific signals with the ANO5 antibodies used, 
most of which have not identified the correct protein at all. For example, Xu et al. 
recently reported that two commercial ANO5 antibodies do not recognize ANO5 
protein [13]. Possible reasons for ANO5 resistance for immunological detection may 
be its low immunogenicity and hydrophobic nature of eight transmembrane domains, 
making the extraction of ANO5 difficult. 
 
Here, we used an SDS-PAGE sample preparation method, where membrane proteins 
are gently extracted using detergents and sonication in low temperature. With mAb 
clone N421A/85, COS-1 cells expressing the construct hANO5wt-V5 showed the 
correct band of 109 kD, which was absent in untransfected cells. In human total 
muscle lysates a ~100 kD band was observed, but also several unspecific bands, some 
of which very close in size to the ANO5 band. In order to confirm ANO5 membrane 
localization and monitor if it might change in patients, tissue fractionation was 
performed. ANO5 was found solely in the membrane fraction in all biopsies studied. 
No accumulation of ANO5 was seen in the insoluble fraction in any of the patients. 
By eliminating most unspecific bands, we were able to quantify ANO5 expression in 
relation to membrane protein markers SERCA(1/2) and DHPR. ANO5 protein was 
clearly reduced in all anoctaminopathy patients, regardless of the mutation. No 
truncated ANO5 protein fragments associated with frameshift mutations were 
detected. The mAb N421A/85 binding site may locate downstream of the c.191dupA 
mutation in exon 5, common in European population, and detection of such truncated 
product would therefore be impossible. However, if the nonsense mutation 
c.1261C>T in exon 13 would produce a truncated protein, it could have been 
recognized by the antibody. We conclude that these mutations likely cause nonsense-
mediated mRNA decay, and loss of ANO5 protein expression. 
 
Hence, we show that the correct ANO5 protein is possible to detect with a specific 
methodology, and that it is expressed in human skeletal muscle as a single major 
isoform of 107 kD. Relatively sharp appearance of the band suggests no major high 
molecular weight covalent post-translational modifications, such as glycosylation, 
which is in agreement with the suggested localization of ANO5 in ER or intracellular 
membrane vesicles [11, 14, 15] (based mostly on detection of tagged constructs in 
transfected cells).  
 
In a recent biochemical study ANO5 was found to be an unstable protein, which 
undergoes constitutive proteasomal degradation [11], and the GDD mutation C356R 
was shown to further decrease ANO5 stability [11]. The myopathy-causing recessive 
ANO5 mutations are distributed throughout the gene. Based on the results described 
here, it seems likely that most, if not all mutations destabilize the protein, either by 
misfolding, compromising its processing in the ER, or affecting its correct 
incorporation into membranes, leading to more rapid degradation and decreased 
ANO5 levels. However, it cannot be ruled out that some mutations may primarily 
affect protein functionality. Different mutations leading to ANO5 instability and 
degradation could manifest as low genotype-phenotype correlation. Certainly, a wider 
spectrum of different ANO5 mutations needs to be analyzed to see which impact they 
have at the protein level. 
 Direct detection of ANO5 by western blotting for diagnostic purposes and for 
determining pathogenicity of ANO5 mutations is now possible. Particularly, the large 
number of LGMD patients with both causative and elusive variants in the ANO5 gene 
would benefit from the protein analysis, making it a suitablesecond tier test after an 
NGS assay. We show that endogenous ANO5 protein is most reliably detected and 
quantitated by using isolated membrane protein fraction. The method described here 
provides a tool for research and further understanding of the ANO5 function. 
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Figure legends 
 
Figure 1. ANO5 western blotting of COS1 expressed ANO5-constructs and total 
muscle lysates 
(A) Western blotting of hANO5wt-V5 constructs expressed in COS1 cells.  
The western blots were detected with V5 mAb (left panel) or ANO5 mAb N421A/85 
(right panel). With both antibodies, a monomer of 109 kD hANO5wt-V5 is observed 
(black arrow), and a >200 band (white arrow), likely representing dimers. (B) ANO5 
western blotting of total muscle lysate. A ~100 kD ANO5 band (arrow) is observed in 
human healthy control muscles, and reduced in anoctaminopathy patients. However, 
several unspecific bands hinder quantitation of specific bands. Asterisk (*) indicates 
truncating mutations. Myosin heavy chain (MyHC) serves as a loading control. (C) 
Localization of ANO5 to muscle membrane fraction. ANO5 (black arrow) clearly 
segregates in the membranous fraction F2 in control muscle samples (C1, C2, C3). 
The same distribution is seen in c.2272C>T homozygote Fin3, albeit with weaker 
signal. The Fin4 patient with c.191dupA/c.2272C>T shows severe decrease of ANO5, 
with no band detected. As expected, no ANO5 is seen in the Ita3 patient. ANO5 
signal was not detected in soluble fraction F1 or insoluble fraction F4. Noteworthy, 
most unspecific bands (white arrows) are in the soluble fraction, and one of them very 
close to the ~100 kD ANO5 band.  
 
  
Figure 2. ANO5 western blotting of muscle membrane fractions 
 (A) Detection of ANO5 in the muscle biopsy membrane fractions (F2) reveals a 
single ~100 kD band, which is clearly reduced in all anoctaminopathy patients (n = 7). 
Asterisk (*) indicates truncating mutations. Membrane proteins SERCA (pooled 
SERCA1 and SERCA2) and DHPR are used as specific loading controls. (B) Graphs 
illustrating the ANO5 expression in individual patients. Bands shown in Figure 2A 
were quantitated, and ANO5/SERCA and ANO5/DHPR ratios were calculated. 
Controls (n = 6) were combined, and their average value was normalized to 1 (column 
1). The expression of ANO5 in all patient samples (columns 2-8) was clearly 
decreased, being lowest in Fin5 (c.191dupA/c.2272C>T) and Ita3 (c.191dupA/ 
c.191dupA). The experiment was performed in duplicate, with similar results. 
ANO5/SERCA, controls: min value = 0.606; max value = 2,021; average = 1,000; 
STDEV = 0,533; ANO5/SERCA, patients: min value = 0,019; max value: 0,297; 
average = 0,123; STDEV = 0,096. ANO5/DHPR, controls: min value = 0,661; max 
value = 1,287; average = 1,000; STDEV = 0,249; ANO/DHPR, patients: min value = 
0,016; max value = 0,289; average = 0,135; STDEV = 0,106.  
 
Table 1. 
Patient 
ID 
M/F Nucleotide change Amino acid 
change   
Muscle 
 
Phenotype 
 
Reference  
Fin1 M [c.2101A>G]; 
[c. 2272C>T] 
p.N701D; 
p.R758C 
Vastus 
lateralis 
Proximal UL, LL weakness; onset at age 
35; CK 1000–3000; EMG myopathy 
Penttilä et. al 
2012 [3] 
Fin2 M [c. 2272C>T]; 
[c.2311_2312delCA] 
p.R758C; 
p.Q771Afs*8 
NA LGMD; onset at age 20; CK 5000–14 000; 
EMG myopathy 
Penttilä et. al 
2012 [3] 
Fin3 M [c. 2272C>T]; 
[c. 2272C>T] 
p.R758C; 
p.R758C 
NA LGMD; onset at age 50; CK 1400–6000; 
EMG myopathy 
Penttilä et. al 
2012 [3] 
Fin4 M [c. 2272C>T]; 
[c. 2272C>T] 
p.R758C; 
p.R758C 
Tibialis 
anterior 
LGMD; onset at age 50; CK 4000 – 
Fin5 F [c.191dupA]; 
[c. 2272C>T] 
p.N64Kfs*15; 
p.R758C 
Vastus 
lateralis 
HyperCKemia, no weakness; onset at age 
40; CK 1000–9000; EMG normal 
Penttilä et. al 
2012 [3] 
Fin6a F [r.1656_2109del]; 
– 
p.Y552*; 
– 
Vastus 
lateralis 
Mild proximal UL, LL weakness; onset at 
age 70; CK 1500–4000; EMG myopathy 
– 
Fra1 M [c.191dupA]; 
[c.191dupA] 
p.N64Kfs*15; 
p.N64Kfs*15 
NA LGMD; onset at age 50; CK 2000–4000; 
dystrophic pattern on the biopsy 
– 
Ita1 M [c.191dupA]; 
[c.1261C>T] 
p.N64Kfs*15; 
p.Q421* 
Quadriceps LGMD; onset age 50; asymmetric proximal 
UL and LL weakness; CK 2200-3000; 
EMG myopathy 
Savarese et 
al. 2015 [6] 
Ita2 F [c.1502delT]; 
[c. 1899-4A>G]  
p.F507Sfs*6; 
predicted to affect 
splicing 
Quadriceps LGMD; onset age 50, asymmetric proximal 
UL and LL weakness; CK 3500; EMG 
myopathy 
Penttilä et. al 
2012 [3] 
Ita3  [c.191dup]; 
[c.191dup] 
p.N64Kfs*15; 
p.N64Kfs*15 
Deltoid  LGMD; onset age 40; asymmetric proximal 
UL and LL weakness; CK 1200 
– 
Abbreviations: UL = upper limb; LL = lower limb; NA = not available 
aOne ANO5 anomaly at mRNA level only; disease control 
 
Table 2. 
Control ID Muscle(s) 
C1 Deltoideus 
C2 Biceps femoris, 
Semimembranosus, 
Sartorius, 
Gracilis 
C3 Biceps femoris, 
Sartorius 
C4 Gastrocnemius 
C5 Gastrocnemius 
C6 Gastrocnemius 
C7 Gastrocnemius 
C8 Gastrocnemius 
C9 Tibialis anterior 
C10 Tibialis anterior 
C11 Tibialis anterior 
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Supplemental Figure 1. Schematic Presentation of the ANO5 Protein. 
Locations of the ANO5 mutations included in this study are shown in the schematic picture. 
Empty circle = truncating mutation; grey circle = missense mutation. 
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Supplemental Figure S2. Characterization of Other ANO5 Antibodies. 
The specificity of three additional ANO5 antibodies was investigated: monoclonal mouse 
antibody (mAb) 2N22 was raised against the sequence SEKLYSRWEQ, human ANO5 aa 
648-657, in the extracellular domain 4, and mAb 5C7 was raised against N-terminal sequence 
aa 1-90: 
MGDPDLLEVLAEEGEKVNKHIDYSFQMSEQSLSSRETSFLINEETMPAKRFNLFLRRRLMFQ
KNQQSKDSIFFRDGIRQIDFVLSYVDDV). The commercial rabbit polyclonal ab181663 
(Abcam) was generated against an undefined sequence within ANO5 N-terminus. 
Noteworthy, the mAb N421A/85 was also generated by using the N-terminal intracellular 
domain aa 1-299 as immunogen.  
A) In COS-1 cells transfected with hANO5WT-V5, the construct monomer of 109 kD is 
observed (black arrow), and also a higher molecular weight dimer band (white arrow), when 
detected with V5 tag antibody. With antibodies 2N22, 5C7 and ab181663, the construct 
monomer is not detected, but instead with mAbs 2N22 and 5C7, an unspecific band of similar 
size in both transfected and untransfected cells is seen (boxed area). In addition, the 2N22 
and 5C7 blots show a band of the size of construct dimer in transfected cells (white arrows). 
However, this band is interpreted as unspecific, as the antibodies fail to recognize the 
monomeric construct. The erroneous labeling is caused by unspecific binding of either 
primary or secondary antibody to the large mass of overexpressed protein, in the absence of 
specific antibody-antigen interaction. 
B) When human muscle samples are detected with mAbs 2N22 and 5C7, no ANO5 band of 
107 kD is detected. Instead, unspecific bands of ~90 kD and ~60 kD are observed similarly in 
controls and patients Fra1 and Ita1 with truncating ANO5 mutations in both alleles. 
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Supplemental Figure S3. ANO5 Expression in Different Normal Control Muscles. 
One ANO5 band of ~100 kD (arrow) is observed in all control samples, indicating that ANO5 
is expressed as a single isoform in all muscles analyzed: gastrocnemius, tibialis anterior, 
biceps femoris, semimembranosus and sartorius. Moderately different levels of expression 
are seen, but there are no systematic differences between the tested muscles to account for 
the differences in muscle involvement in LGMD2L.  
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Supplemental Figure S4. ANO5 Immunohistochemistry. 
Frozen muscle sections (8 µm) were prepared on slides, and treated in different ways in order 
to obtain ANO5-specific labelling. The slides were fixed either with 4% paraformaldehyde 
(PFA) for 10 min, formalin for 15 min, ice-cold acetone for 10 min, ice-cold methanol for 10 
min, or were stained without fixing. A subset of the PFA/formalin fixed slides were subjected 
to antigen retrieval with EDTA buffer pH 8.0, or citrate buffer, pH 6.0: the slides in retrieval 
buffer solution in plastic jars were brought to boiling temperature for 5 min in a microwave 
oven, and let cool down in the buffer solution for 20-30 min prior to washing with PBS. The 
slides were immunostained with ANO5 mAb N421A/85 or pAb ab181663, using either manual 
immunofluorescent detection, primary antibody incubation overnight at +8°C, or automated 
DAB-immunohistochemistry with HRP-conjugated secondary antibodies (Ventana 
Benchmark, Ventana Medical Systems, Tucson, AZ). However, all the immunohistochemical 
experiments failed to show ANO5-specific labelling, as positive and negative controls were 
identical on examination. Examples are shown in figures (A) and (B). 
A) Immunofluorescent analysis using PFA-fixation and ANO5 mAb N421A/85. The sections 
were pretreated with 1% SDS prior to primary Ab incubation, in order to achieve protein 
denaturation and epitope exposure. The samples showed diffuse cytoplasmic labeling with 
ANO5 (red), which turned out to be unspecific as it was similar in controls and patient Ita1 
with two truncating ANO5 mutations. Calsequestrin (green) was used as a sarcoplasmic 
reticulum marker. Scale bar 100 µm. 
B) Automated DAB-immunohistochemistry with pAb ab181663 (dilution 1:50, no fix, 
amplification) similarly showed cytoplasmic labeling (brown), which was not reduced in patient 
Ita1, and hence unspecific. Scale bar 20 µm. 
